# Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

> **NCT01237067** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 77 (actual)

## Conditions studied

- Ovarian Cancer
- Breast Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT01237067
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-07
- **Primary completion:** 2014-11-16
- **Final completion:** 2019-12-12
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237067, "Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01237067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*